- Ursodeoxycholic acid (UDCA), a secondary bile acid used primarily to treat liver and gallbladder disorders, has become an essential therapeutic agent in managing conditions such as primary biliary cholangitis and cholesterol gallstones due to its hepatoprotective and anti-inflammatory properties
- The increasing demand for ursodeoxycholic acid is largely driven by the rising global prevalence of liver diseases, increasing awareness of hepatobiliary health, and growing prescription rates for chronic liver conditions, especially in aging populations
- North America dominated the ursodeoxycholic acid market with the largest revenue share of 39.4% in 2024, attributed to high diagnosis rates, well-established healthcare infrastructure, and increasing adoption of advanced treatment regimens, with the U.S. witnessing significant demand from both hospitals and specialty clinics
- Asia-Pacific is expected to witness the fastest growth in the ursodeoxycholic acid market during the forecast period, supported by a rising burden of liver disorders, improving healthcare access, and expanding pharmaceutical manufacturing capacities in countries such as China and India
- The synthetic segment dominated the ursodeoxycholic acid market with a market share of 65.9% in 2024, driven by its cost-effectiveness, stable supply chain, and increasing preference among generic drug manufacturers
